Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGX148 (CD39+CD103+CD8+ TIL) with or without PD-1 siRNA in advanced solid tumors
NCT05902520Phase 1Active, not recruiting
- Sponsor
- AgonOx, Inc.
- Start
- Jun 2023
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Tumor-Infiltrating Lymphocytes (TILs), Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AGX-148 in head and neck squamous cell carcinoma (HNSCC), melanoma, gynecologic cancer and 3 more (2 arms), sponsored by AgonOx, Inc. Primary endpoint: Safety of DP CD8 TIL at 12 weeks. Started Jun 2023; status: active, not recruiting.
02
Drugs
AGX-148
03
Conditions
head and neck squamous cell carcinoma (HNSCC)melanomagynecologic cancercolorectal cancer (CRC)lung cancer
Beyond the preview
Go deeper on NCT05902520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05902520.